Participant flow

PTK/ZK as Post Transplant Maintenance Therapy in Patients With Multiple Myeloma · Source last updated 2014-09-17

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

groups

1. description

   Initially patients will receive a dose of 500mg (2, 250mg tablets) in the morning and 250mg (1, 250mg tablet) in the afternoon for 2 weeks (cycle 1, days 1-14), then 500mg (2, 250mg tablets) bid for 2 weeks (cycle 1, days 15-28) and finally 750mg (3, 250mg tablets) in the morning and 500mg (2, 250mg tablets) in the afternoon for the remainder of treatment duration (cycle 2, day 1 and onwards). Each 28 days of drug administration will constitute one cycle of therapy.

   id

   FG000

   title

   PTK787/ZK 222584

periods

1. milestones

   1. achievements

      1. group Id

         FG000

         num Subjects

         21

      type

      STARTED

   2. achievements

      1. group Id

         FG000

         num Subjects

         21

      type

      COMPLETED

   3. achievements

      1. group Id

         FG000

         num Subjects

         0

      type

      NOT COMPLETED

   title

   Overall Study

recruitment Details

The study opened to participant enrollment on 09/21/2005 and closed to participant enrollment on 06/17/2008.

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice